Medicines: Get integrated scientific advice from the MHRA and NICE

AI Summary

The Medicines and Healthcare products Regulatory Agency (MHRA) and the National Institute for Health and Care Excellence (NICE) have introduced the Integrated Scientific Advice service to assist pharmaceutical companies. This service provides coordinated guidance on evidence requirements for market authorization and health technology assessments through a streamlined process. Operating under the regulatory framework of the Human Medicines (Amendment etc.) (EU Exit) Regulations 2020, the initiative specifically offers fee reductions for UK-based small and medium-sized enterprises to support innovation. Because this is a guidance document for a voluntary advisory service rather than an enforcement action, there are no inspection dates or violations reported. Instead, the service aims to prevent issues such as conflicting regulatory advice, optimized clinical development plans, and unforeseen market access delays. To participate, companies must follow a specific sequence of actions: verify project eligibility, submit a formal request and a comprehensive briefing book, and pay a consolidated fee. The process culminates in a joint meeting with experts and the delivery of a single integrated advice report within approximately 80 to 115 working days. This report aligns regulatory and health technology requirements, providing companies with a clear roadmap for evidence generation. Although the advice is not legally binding, it is designed to enhance the credibility of clinical plans and accelerate patient access to new medicines by clarifying complex requirements early in the development lifecycle.